Moderna is creating a new category of transformative medicines based on messenger RNA, or mRNA. The company's pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
  • TickerMRNA
  • ISINUS60770K1079
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Fatma Agnès Hamdani ...
  • Jean Sassus
  • Martial Descoutures
  • Olfa Taamallah
  • Samantha Jeary
  • Sebastien Malafosse
  • Steven Gould
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/29/2020

...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : A reassuring message

>Pending full publication of phase I data - We organised a conference call with Moderna’s management yesterday. Ahead of the company’s Science day scheduled for 2 June, CEO Stéphane Bancel went into detail about the intermediate clinical results of its phase I trial evaluating MRNA-1273, its candidate vaccine for COVID-19. In short, these intermediate results showed an immune response (immunogenicity) and the capacity to synthesise neutralising antibodies. In ter...

Fatma Agnès Hamdani ...
  • Jean Sassus
  • Martial Descoutures
  • Olfa Taamallah
  • Samantha Jeary
  • Sebastien Malafosse
  • Steven Gould
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 29/05/2020

...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Un discours rassurant

>Dans l’attente de la publication complète de la phase 1… - Nous organisions hier une conférence téléphonique avec le management de Moderna. En amont de sa journée « Science » prévue le 2 juin, Stéphane Bancel (CEO) est revenu précisément sur les résultats cliniques intermédiaires de sa phase 1 évaluant MRNA-1273, son candidat vaccin contre le COVID-19. Brièvement, et pour rappel, ces résultats intermédiaires montraient une réponse immunitaire (immunogénicité) et la ...

ValuEngine Rating and Forecast Report for MRNA

ValuEngine Rating and Forecast Report for MRNA

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

ullish Tape Despite Inconsistencies Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods. · S&P 500 Short-Term Levels. We continue to respect the bullish tape, however the S&P 500 remains in the 2855-2900 resistance zone while forming a bearish rising wedge pattern. This pattern results in a breakdown roughly 70% of the time. Still, support at 2760 would need t...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : A reassuring message

>Pending full publication of phase I data - We organised a conference call with Moderna’s management yesterday. Ahead of the company’s Science day scheduled for 2 June, CEO Stéphane Bancel went into detail about the intermediate clinical results of its phase I trial evaluating MRNA-1273, its candidate vaccine for COVID-19. In short, these intermediate results showed an immune response (immunogenicity) and the capacity to synthesise neutralising antibodies. In ter...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Un discours rassurant

>Dans l’attente de la publication complète de la phase 1… - Nous organisions hier une conférence téléphonique avec le management de Moderna. En amont de sa journée « Science » prévue le 2 juin, Stéphane Bancel (CEO) est revenu précisément sur les résultats cliniques intermédiaires de sa phase 1 évaluant MRNA-1273, son candidat vaccin contre le COVID-19. Brièvement, et pour rappel, ces résultats intermédiaires montraient une réponse immunitaire (immunogénicité) et la ...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Initial data offer hope – capital increase of $ 1.34bn

>Positive interim data - Moderna yesterday afternoon published interim phase I data for its SARS-COV2 vaccine candidate. Although these are interim data with very few patients, we can at this stage highlight the quality of these data which will clearly have to be confirmed going forward. Briefly, we note the design of the trial, the primary endpoint being the safety of the vaccination schedule followed by initial signs of efficacy (immunogenicity and neutralising anti...

Martial Descoutures ...
  • Sebastien Malafosse

Moderna : Des premiers résultats qui donnent de l’espoir - AK de 1.34 Md$

>Des résultats intermédiaires positifs - Moderna publiait hier après-midi ses résultats intermédiaires de phase 1 évaluant son candidat vaccin contre SARS-COV2. Bien qu’intermédiaire avec très peu de patients, nous pouvons souligner la qualité à ce stade de ses résultats qui devront bien évidemment être confirmés par la suite. Rappelons juste brièvement le design de l’étude qui avait pour premier objectif la sécurité du schéma vaccinal suivi des premiers signes d’effi...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Key Resistance As we have outlined in recent weeks, our base case continues to be for near-term consolidation while the market is in a “wait-and-see” phase as it relates to states re-opening. The S&P 500 is again testing key resistance at the 61.8% Fibonacci retracement level of 2934.49 and also the 2950-3000 level we previously identified. We continue to have concerns that lead us to believe the market is not yet out of the woods, however these concerns are counterbalanced by a number of positive developments. When it comes down to it, key support levels mentioned last week i...

Fatma Agnès Hamdani ...
  • Jean Sassus
  • Martial Descoutures
  • Olfa Taamallah
  • Samantha Jeary
  • Sebastien Malafosse
  • Steven Gould
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/29/2020

...

Fatma Agnès Hamdani ...
  • Jean Sassus
  • Martial Descoutures
  • Olfa Taamallah
  • Samantha Jeary
  • Sebastien Malafosse
  • Steven Gould
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 29/05/2020

...

Alain William ...
  • Alexandre Iatrides
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Pierre Tegner
  • Sebastien Malafosse
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/19/2020

...

Alain William ...
  • Alexandre Iatrides
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Pierre Tegner
  • Sebastien Malafosse
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 19/05/2020

...

Benoit Valleaux ...
  • Bruno Cavalier
  • Emmanuel Matot
  • Jean Sassus
  • Martial Descoutures
  • Roland Pfaender,MBA,CFA,CCRA
  • Sebastien Malafosse
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/11/2020

Like a phoenix rising from its ashes, the US shale industry weathered the 2014 crisis and even continued to gain market share. Five years on, the sector has to contend with a veritable slump in WTI prices and this time around, there will be “a problem in Houston”. This time shale output is likely to fall and drilling equipment manufacturers will not escape completely unscathed, notably because of the risk of asset impairments. Once again, resilience will be measured by the ability to ...

ValuEngine Rating and Forecast Report for MRNA

ValuEngine Rating and Forecast Report for MRNA

ValuEngine Rating and Forecast Report for MRNA

ValuEngine Rating and Forecast Report for MRNA

Thanks to a better fundamental star rating, MODERNA INCO. sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to MODERNA INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date May 15, 2020, the closing price was USD 66.69 and its expected value was estimated at USD 43.92.

ValuEngine Rating and Forecast Report for MRNA

ValuEngine Rating and Forecast Report for MRNA

ValuEngine Rating and Forecast Report for MRNA

ValuEngine Rating and Forecast Report for MRNA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch